About me
Dr. Madan attended medical school at Gajra Raja Medical College in India prior to completing an internal medicine residency and a hematology and oncology fellowship at University of Alabama. He is board certified in internal medicine, hematology, and medical oncology.
As a hematologist and oncologist, Dr. Madan cares for patients with a variety of conditions, including benign and malignant hematology disorders (leukemia, lymphoma), melanoma, sarcoma and cancers of the breast, colon, kidney, liver, lung, prostate and ovaries at MedStar Georgetown Cancer Institute at MedStar Southern Maryland Hospital Center.
Philosophy of care
Dr. Madan believes in providing the latest, state-of-the-art, evidence-based cancer care with compassion, empathy, and respect. He uses a multidisciplinary approach in managing all malignancies to optimize patient outcomes and supports patients and their families in their respective goals of care.
“Our vision is to make cancer care in Southern Maryland highly accessible, and available to the community. Cancer affects patients and their families, and by being their partner in this difficult journey, I hope to alleviate some of the stress, and anxiety associated with this disease. "
Clinical areas of focus
- Adenocarcinoma Of Lung
- Bladder Cancer
- Breast Cancer
- Colorectal Malignancy
- Esophageal Cancer Chemotherapy
- Kidney Cancer
- Leukemia
- Melanoma
- Mesothelioma
- Non Small Cell Lung Cancer
- Pancreas Cancer
- Prostate Cancer
- Rectal Cancer
- Sarcoma
- Seminoma
- Testicular Cancer
Conditions and procedures
Conditions I treat
- Abdominal Cancer
- Adenocarcinoma Of Lung
- Adenocarcinoma Of The Bladder
- Advanced Malignancies
- Appendiceal Cancer
- Autoimmune Cytopenia
- Benign Neoplasm Bone
- Bile Duct Mass
- Bladder Cancer
- Brain Metastases
- Breast Cancer
- Cancer
- Cancer Pain
- Cancer Survivor
- Carcinoma Of Unknown Primary
- Colorectal Malignancy
- Ductal Carcinoma In Situ (DCIS)
- Endocrine Complications Of Cancer Therapy
- Endometrial Cancer
- Gallbladder Cancer
- Gastroesophageal Junction Cancer
- Gastrointestinal (GI) Cancer
- Genitourinary Cancers
- Head And Neck Tumors
- Hemolytic Uremic Syndrome
- Hereditary Cancer Risk
- Intestinal Cancer
- Kidney Cancer
- Large Cell Cancer Of The Lung
- Large Cell Neuroendocrine Tumors
- Leukemia
- Liver Cancer
- Liver Metastases
- Long Term Side Effects Of Cancer Treatment
- Lung Cancer
- Lung Mass
- Lymphoma
- Lymphoproliferative Disorder
- Malignant Carcinoid Tumor Of Colon
- Malignant Lung Tumors
- Mediastinal Lymphadenopathy
- Melanoma
- Merkel Cell Carcinoma
- Mesothelioma
- Muscle Invasive Bladder Cancer
- Myeloproliferative Diseases
- Nodular Lymphocyte Predominant Hodgkin Lymphoma
- Non Germinomatous Germ Cell Tumor
- Non Hodgkin Lymphoma
- Non Small Cell Lung Cancer
- Non-Muscle Invasive Bladder Cancer
- Pancreas Cancer
- Plasma Cell Dyscrasia
- Prostate Cancer
- Pulmonary Metastases
- Rectal Cancer
- Refractory Anemia With Excess Blasts
- Refractory Cytopenia
- Relapsed Hodgkin Lymphoma
- Relapsed Non Hodgkin Lymphoma
- Sarcoma
- Seminoma
- Side Effects Of Cancer Treatment
- Smoldering Multiple Myeloma
- Solid Tumors
- Stomach Cancer
- Testicular Cancer
- Thoracic Cancer
- Tracheal Cancer
- Waldenstrom Macroglobulinemia
Procedures I perform
- Abdominal Cancer Chemotherapy
- Adjuvant Chemotherapy
- Adjuvant Chemotherapy
- Anorectal Cancer Chemotherapy
- Appendiceal Cancer Chemotherapy
- Biliary Tract Cancer Chemotherapy
- Biological Targeted Therapy
- Bladder Cancer Chemotherapy
- Brain Cancer Chemotherapy
- Breast Cancer Biological Targeted Therapy
- Breast Cancer Chemotherapy
- Cancer Chemotherapy
- Cancer Genomics
- Cervical Cancer Chemotherapy
- Chemoradiation
- Colon Cancer Chemotherapy
- Colorectal Cancer Chemotherapy
- Early Detection Of Cancer
- Endometrial Cancer Chemotherapy
- Esophageal Cancer Chemotherapy
- Gallbladder Cancer Chemotherapy
- Head And Neck Cancer Chemotherapy
- Hormone Based Chemotherapy
- Hypopharyngeal Cancer Chemotherapy
- Laryngeal Cancer Chemotherapy
- Liquid Biopsy Testing
- Liver Cancer Chemotherapy
- Mouth Cancer Chemotherapy
- Nasal Cavity Cancer Chemotherapy
- Nasopharyngeal Cancer Chemotherapy
- Non Steroidal Aromatase Inhibitors
- Ovarian Cancer Chemotherapy
- Pancreatic Cancer Chemotherapy
- Personalized Cancer Therapy
- Pleural Cancer Chemotherapy
- Prostate Cancer Chemotherapy
- Renal Cell Carcinoma Immunotherapy
- Small Cell Lung Cancer Chemotherapy
- Small Intestine Cancer Chemotherapy
- Stomach Cancer Chemotherapy
- Systemic Therapy
- Targeted Molecular Therapy
- Testicular Cancer Chemotherapy
- Throat Cancer Chemotherapy
- Tongue Cancer Chemotherapy
- Uterine Cancer Chemotherapy
- Vaginal Cancer Chemotherapy
Insurance
MedStar Medical Group accepts most major health insurance plans. If you are uncertain as to whether your individual health insurance plan is accepted at MedStar Medical Group, please call your insurance company.
-
List of insurance plans we accept
- UnitedHealthcare Medicare Adv/Special Needs Plans
- UnitedHealthcare and AARP Medicare Complete Plans/ UHC Group Medicare Advantage Plans HMO, POS, PPO"
- United Healthcare Options (PPO) (includes Empire PPO, GEHA, Compass Rose)"
- UHC Community Plan of MD
- Private Health Care Systems (PHCS) (PPO)
- Medicare Fee for Service
- Kaiser Virginia Premier
- Kaiser PermanenteSelect-Added Choice
- Kaiser Permanente Signature-Added Choice
- Kaiser Permanente Signature
- Kaiser Permanente Select
- Kaiser Permanente Medicare Plus (Medicare Supplemental Plan)
- Kaiser Permanente Flexible Choice POS
- Kaiser MD Medicaid MCO
- Cigna HealthSpring Medicare Advantage
- CFBCBS Federal Employee Program (Std/Basic PPO/Blue Focus)
- CFBCBS EPO
- Blue Choice Advantage & Healthy Blue (HMO, POS)"
- Aetna Better Health of Maryland
- Mamsi Life & Health (Indem./PPO)
- Optimum Choice Preferred (POS) & OCI Direct (HMO)
- M.D. IPA Preferred (POS)
- M.D. IPA (HMO)
- United Student Resources
- United Healthcare Choice Plus
- United Healthcare Select Plus (POS)
- United Healthcare Select HMO - EPO/NPP
- United Healthcare Choice
- Tricare for Life (Medicare Supplemental Plan)
- Tricare Prime
- MedStar Select (MedStar Associates' Plan)
- MedStar Family Choice - Maryland Health Choice
- FIRST HEALTH
- Coventry Health Care National Network PPO
- First Health PPO
- Coventry of Delaware HMO/PPO
- Coventry Health Care of Virginia
- CIGNA Indemnity
- Great-West Healthcare POS/CIGNA
- CIGNA POS/Network POS
- CIGNA HMO & Network (HMO)
- POS OA & OA Plus
- Network OA
- CIGNA HMO Open Access (OA)
- Choice Fund PPO
- PPO and PPO Plus
- CIGNA EPO
- CFBCBS (NCA) Indemnity
- CFBCBS Maryland Indemnity or PPO
- HealthyBlue PPO
- CFBSBC Blue Preferred PPO
- CFBCBS Maryland Point of Service Plan (MPOS)
- CFBCBS Blue Choice Opt Out Plus Open Access (POS)
- CFBCBS BlueChoice HMO
- BlueChoice Open Access
- CFBCBS Blue Choice Opt Out Open Access
- Aetna Worker's Compensation Network
- Aetna Medicare Advantage HMO & PPO Plans
- Innovation Health: Indemnity
- Aetna Traditional Choice (PPO)
- Innovation Health: PPO
- Aetna Open Choice (PPO)
- Aetna Student Health Insurance
- Innovation Health: POS Plus
- Aetna Managed Choice (POS)
- Innovation Health: Open Network Only Plus
- Aetna Elect Choice/ Open Access (POS)
- Aetna Quality Point of Service (POS)
- Aetna Elect Choice/ EPO (Aetna Health Fund) Innovation Health: Network Only Plus
- Open EPO Plus
- Opoen HMO Option
- Open HMO
- Innovation Health: POS
- Aetna HMO-Open Access/Select OA/HealthFund/Health Network Option OA
- Open POS II
- Innovation Health: Open POS Plus
- Choice POS & Choice POS II
- Aetna Managed Choice Open Access (POS)
- Aetna Innovations: HMO & EPO Plus
- Select HMO/HealthFund/Health Network
- Aetna HMO
Videos
Education
Board Certification: American Board of Internal Medicine, Hematology
Board Certification: American Board of Internal Medicine, Internal Medicine
Board Certification: American Board of Internal Medicine, Medical Oncology
Fellowship Program: University of Alabama Birmingham Hospital (2017)
Residency Program: University of Alabama Birmingham HospitalHighlands (2014)
Medical School: Gajra Raja Medical College (2009)
Hospital affiliations
News and publications
- Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic
Ankit Madan, Joshua Siglin, Aleem Khan
Cancer Medicine 2020; 9(24)9205-9218
A narrative review of the evolving role of immunotherapy in the management of esophageal and gastric cancer
Ankit Madan, Hope E. Uronis , John H. Strickler
J Gastrointest Oncol 2022;13(4) 2007-2019
Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients
Ankit Madan, Benjamin Jones, Rodolfo Bordoni, Mansoor Saleh, Mary Jerome, Deborah Miley, Bradford Jackson, Francisco Robert
Cancer Chemother Pharmacol 2016 Sep;78(3):509-15
Localized small cell carcinoma of the breast: a case report and review of current evidence
Linsey Atchison,Thomas Hardy,Tara Mancl, Brian Quaranta, Ankit Madan
Case Rep Oncol 2021;14:761–766
CNS Involvement in a Patient with Chronic Myeloid Leukemia
Marcus A. Healey, Daniel J. Allendorf , Uma Borate , and Ankit Madan
Volume 2021 |Article ID 8891376 Case reports in hematology
CXCR2 Mediates Distinct Neutrophil Behavior in Brain Metastatic Breast Tumor
Simrit Safarulla, Ankit Madan, Fei Xing, Arvind Chandasekaran
Cancers 2022, 14(3), 515
Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma
Arindam P. Ghosh, Christopher D. Willey, Joshua C. Anderson, Karim Welaya, Dongquan Chen, Amitkumar Mehta, Pooja Ghatalia, Ankit Madan, Gurudatta Naik, Sunil Sudarshan, Guru Sonpavde
Oncotarget 2017 Apr 25; 8(17): 29220–29232.
Prevalence of Measurable disease in metastatic castration-resistant prostate cancer
Guru Sonpavde, Ankit Madan, Mary K. Baker, Jori E. May, Gurudutta Naik, Sejong Bae
Clin Genitourin Cancer. 2017 Apr 26.
Genomics and precision medicine: kidney cancer
Ankit Madan, David M.Nanus
Book: Genomic and Precision Medicine (Third Edition)
2022, Pages 285-295
Adult Wilms’ Tumor chapter
Book: Rare Genitourinary tumors, Lance Pagliaro
Ankit Madan, Guru Sonpavde
DOI 10.1007/978-3-319-30046-75